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Abstract 
OBJECTIVE: During pregnancy, metabolic interactions must be adapted, though neuroendocrine 
mechanisms for increased food intake are poorly understood. The objective of this study was to 
characterize differences in insulin, leptin, and agouti-related protein (AgRP) levels in serum and 
cerebrospinal fluid (CSF) in pregnant women with normal weight (NW) and pregnant women with 
overweight (OW) or obesity (OB). Placenta as a source for increased peripheral AgRP levels during 
pregnancy was also investigated. 
 
METHODS: Women were recruited at admission for elective cesarean section. Insulin, AgRP, and 
leptin were measured in serum and CSF from 30 NW, 25 OW, and 21 OB at term. Serum during 
pregnancy and placenta at term were collected for further AgRP analysis. 
 
RESULTS: Immunohistology showed placental production of AgRP and serum AgRP levels increased 
throughout pregnancy. CSF AgRP, leptin, and insulin levels were higher in OW and OB than NW. 
Serum leptin and insulin levels were higher and AgRP lower in OB than NW. 
 
CONCLUSIONS: High serum AgRP levels might protect from the suppressive effects of leptin during 
pregnancy. Pregnant women with OB and OW might further be protected from the suppressive effect 
of leptin by high CSF AgRP levels. Evidence was found, for the first time, of human placental AgRP 
production mirrored by levels in the circulation. 
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The rising tide of obesity in women of reproductive age is of particular concern. In the US, the 
prevalence is 32.4%—an increase of 70% over a 10-year period1. Among pregnant women in the US, 
the prevalence of overweight and obesity has almost doubled in the last 20 years, and nearly half of 
women in the US begin their pregnancies overweight or obese1. An elevated pre-pregnancy BMI is 
associated with a linear increase in adverse maternal and fetal outcomes2. High pre-gravid BMI and 
excessive gestational weight gain (GWG) are predictors of short-term postpartum morbidity and 
higher postpartum weight retention; the latter increases the risk of future pregnancies and of lifelong 
obesity3. 
Pregnancy is characterized by increased metabolism and neuroendocrine changes. For example, 
food intake is increased and thermogenesis is suppressed4,5 to produce a favorable energy balance for 
the growth and development of fetal and maternal tissues and to increase fat stores in preparation for 
lactation. However, the mechanisms of the increased food intake are poorly understood. The 
hypothalamus is the primary brain region regulating energy homeostasis. The arcuate nucleus, a key 
hypothalamic area involved in food intake and body weight, consists of two neuronal populations with 
opposite effects on food intake: neurons that co-express agouti-related protein (AgRP) and 
neuropeptide Y (NPY), which stimulate food intake, and neurons that when activated co-express pro-
opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART), which inhibit 
food intake6. Both AgRP/NPY and POMC neurons are important target areas for insulin and leptin and 
act as sensors of peripheral energy stores. 
During pregnancy, serum leptin levels are elevated7,8. Leptin is well known as an adipocyte-
derived hormone that reduces appetite, but the level of hyperleptinemia observed in pregnant humans 
and animals suggest that leptin insensitivity is a feature of pregnancy. In humans, leptin seems to be 
synthesized by the placenta, as the ob gene is expressed in syncytiotrophoblasts, trophoblasts, and 
amnion cells9. Consistent with placental production, leptin levels are highest during the second 
trimester of human pregnancy and fall abruptly postpartum10. Leptin usually reduces food intake by 
binding to the long form of the receptor (OB-Rb) in the hypothalamus and modulating the activity of 
key neurons, including AgRP and POMC neurons, that regulate energy expenditure and appetite. 
Leptin binds to POMC and the POMC-derived MSH peptides that decrease calorie consumption, and 
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suppresses release of AgRP. This orexigenic peptide stimulates food intake by counteracting the 
effects of alpha-MSH at brain melanocortin receptors11. This hypothalamic bioactivity requires 
transport of leptin into the CNS. Leptin is too large to cross the blood–brain barrier through simple 
diffusion and is believed to get into the brain via a saturable transport system and carried by the short 
form of the leptin receptor11. Leptin may also have access to brain areas outside the blood–brain 
barrier. Despite the hyperleptinemia of pregnancy, calorie consumption and appetite increase during 
gestation, pointing to the existence of a leptin-resistant state at the level of the hypothalamus that is 
likely modified to assure that the metabolic needs of the developing fetus are met12. 
In women, insulin resistance gradually develops during pregnancy to ensure adequate nutrition for 
the fetus, and insulin secretion increases to maintain normal glucose metabolism. In lean women, the 
changes in insulin sensitivity during pregnancy are inversely related to the increasing maternal fat 
mass13. Because it is released immediately in response to food intake, insulin is a likely candidate for 
feedback mechanisms that down-regulate appetite and thereby end food intake. Entry of insulin into 
the brain is likely facilitated by an insulin receptor-mediated transporter, which functions mainly at 
physiological levels of plasma insulin14. Insulin receptors are found in several brain regions but do not 
regulate glucose metabolism in the CNS. Interestingly, the CSF/serum insulin ratio is significantly 
associated with whole-body insulin sensitivity, and insulin transport into the CSF is reduced in insulin-
resistant subjects15. 
Insulin mainly acts in the arcuate nucleus and binds to its receptors highly expressed in 
NPY/AgRP and POMC/CART neurons. Because it decreases NPY and stimulates POMC expression, 
insulin promotes reduced food intake16. Insulin and leptin both activate POMC neurons, but they seem 
to differentially regulate AgRP, with insulin stimulating and leptin inhibiting its synthesis17. AgRP 
may be important during pregnancy, both for maternal energy expenditure and for fetal development. 
AgRP expression in the hypothalamus and placenta, and its serum and CSF levels, increase during 
pregnancy, and the placenta is the main peripheral source of AgRP18. 
The aim of this study was to characterize the differences in insulin, leptin, and AgRP levels in 
serum and CSF in relation to BMI, energy intake, weight gain, and insulin sensitivity in normal 
weight, overweight, and obese pregnant women at term. 
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Methods 
Subjects 
This prospective study was approved by the local ethics committee at the University of 
Gothenburg (nr 402–08) and performed at Sahlgrenska University Hospital, Gothenburg, Sweden. 
Written informed consent was obtained from all subjects before participation. Subjects were 74 
healthy women with uncomplicated pregnancies at term (age 33.4 ± 0.5 yr, mean ± SEM) divided into 
three groups based on BMI at the first antenatal visit: normal weight (18.5–24.9 kg/m2, n = 30), 
overweight (25.0–29.9 kg/m2, n = 21), and obese (≥30 kg/m2, n = 25). Subjects were screened by 
medical history before participation. All subjects were nonsmokers in good general health who were 
on no medications. Subjects were free from past or present major psychiatric disorders, alcoholism, 
neurological disease, diabetes, and renal and hepatic disease. Subjects were excluded if they had used 
weight loss supplements or dieted during the 6 months before the study. Subject characteristics are 
presented in Table 1. 
Protocol 
All pregnant subjects were undergoing elective cesarean section the morning after an overnight 
fast. Before surgery, a self-administered dietary questionnaire was used to assess energy intake during 
the 3 previous months19. The questionnaire has a semi-quantitative food frequency design and was 
validated in Swedish men and nonpregnant women against a 4-day food record and 24-h energy 
expenditure and nitrogen excretion. From these comparisons, valid estimates of energy intake were 
obtained in normal weight, overweight, and obese subjects19. 
A 10-ml venous blood sample was taken by venipuncture before infusion of 1.0 liter of Ringer-
acetate solution. After the infusion and before spinal anesthesia, the patient was placed in a seated or 
lying position, an introducer needle was inserted into the interspinous ligament at L3-4, and a 25-
gauge Whitacre needle was inserted through the introducer into the subarachnoid space. Ten milliliters 
of CSF were removed with a 10-ml syringe. Hemorrhagic samples were excluded. In all groups, the 
first 0.5 ml of CSF obtained was discarded before collection of the sample for study. All CSF samples 
were immediately transferred to polyethylene tubes and placed on ice. Samples were then centrifuged, 
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aliquoted, and stored at –80 ° C until assays were performed. The serum samples obtained 
immediately before CSF collection were similarly centrifuged, aliquoted, and stored at –80 ° C. 
Hormone assays 
Biochemical analyses were performed by the accredited (SWEDAC ISO 15189) Laboratory for 
Clinical Chemistry and the Neurochemistry Department and Diagnostics Research Unit at Mölndals 
Sjukhus, Sahlgrenska University Hospital. Insulin was measured with the Elecsys kit (Roche, Cat. no. 
12017547122) on a fully integrated Cobas 6000 analyzer (Roche). ELISA kits were used for agouti-
related protein (AgRP, R&D Systems, Cat. no. DAGR00), pro-opiomelanocortin (POMC, 
MyBioSource, Cat no. MBS2508350), and leptin (R&D Systems, Cat. no. DLP00). All assays were 
performed as recommended by the manufacturer. The ELISA plates were read on a Vmax plate reader 
(Molecular Devices), and the concentrations were determined with Softmax software (Molecular 
Devices). Insulin, AgRP, and POMC were analyzed in undiluted samples. For analysis of leptin, CSF 
samples were diluted 2-fold and serum samples 100-fold. The quantitative insulin sensitivity check 
index (QUICKI) was calculated as 1/(Log(s-insulin)(mU/l) + Log(p-glucose)(mmol/l))20. 
Statistical analyses 
The results are given as means ± SEM. Statistical analyses were done with IBM SPSS Statistics 21 
(SPSS, Chicago, IL). Multiple comparisons were evaluated by one-way ANOVA and Turkey’s post 
hoc test. Pair-wise comparisons were evaluated by independent sample t test. Correlations were 
examined by linear regression analysis with Pearson’s correlation test. For all comparisons, statistical 
significance was defined as P < 0.05. 
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Results 
Maternal characteristics  
Characteristics of the study participants are presented in Table 1. The ages of the participants did 
not differ; the mean age was about 34 years. GWG and gestational age at birth did not differ 
significantly between the groups. However, birth weight was significantly higher in the obese group 
than in the normal weight group. Self-reported total energy intake did not differ between the three 
groups (Table 1), nor did the intake of carbohydrate, fat, and protein during the last 3 months of 
pregnancy (data not shown). 
Insulin sensitivity 
All women were normoglycemic, and their fasting plasma glucose levels did not differ (Table 2). 
Serum insulin levels were significantly higher, and QUICKI was significantly lower, in obese women 
than in normal weight women. As expected, QUICKI correlated negatively with BMI (r = –0.42, P < 
0.001), plasma glucose (r = –0.68, P < 0.001), and serum insulin (r = –0.87, P < 0.001) in the total 
study population. QUICKI values also correlated with serum leptin (r = –0.53, P < 0.001), CSF leptin 
(r = –0.36, P < 0.01), CSF/serum leptin ratio (r = –0.42, P < 0.001), CSF insulin (r = –0.47, P < 0.001) 
and birth weight (r = –0.24, P < 0.05). Interestingly, insulin sensitivity correlated with CSF AgRP ( = 
–97.29, r = -0.27, P < 0.05) (Figure 2A) and the CSF/serum insulin ratio (r = 0.34, P < 0.01).  
Serum and CSF insulin levels 
As described in Table 2, serum insulin concentrations were significantly higher in obese women 
than in normal weight women. Similarly, CSF insulin concentrations were significantly higher in both 
overweight and obese women than normal weight women (Table 3). Interestingly, the CSF/serum 
insulin ratio was significantly lower in obese women than normal weight women (Figure 1A). CSF 
insulin correlated with BMI (r = 0.24, P < 0.05). By simple linear regression analysis, serum insulin 
concentration and CSF leptin were positively related ( = 27.50, r = 0.28, P < 0.05) (Figure 2B). 
Serum insulin also correlated with BMI (r = 0.38, P = 0.001), plasma glucose (r = 0.36, P < 0.01), CSF 
leptin (r = 0.40, P < 0.01), serum leptin (r = 0.38, P < 0.01). The CSF insulin concentration was 
significantly associated with serum glucose ( = 0.051, r = 0.29, P < 0.05) (Figure 2C), serum leptin (r 
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= 0.26, P < 0.05), and CSF leptin (r = 0.26, P < 0.05). Serum AgRP correlated negatively (r = –0.28, P 
< 0.05), and CSF AgRP correlated positively (r = 0.28, P < 0.05), with serum insulin. CSF insulin was 
significantly associated with the CSF/serum leptin ratio (r = 0.26, < 0.05) and serum insulin (r = 0.033, 
P < 0.05). 
Serum and CSF leptin levels 
Both serum and CSF leptin levels were significantly higher in overweight and obese women than 
in normal weight women (Table 3), although the level was much lower in CSF than in serum (Table 
3), and both correlated with BMI (r = 0.49, P < 0.001)  (r = 0.40, P < 0.001). CSF leptin was also 
associated with GWG (r = 0.25, P < 0.05). The CSF/serum ratio was significantly lower in the obese 
women than in normal weight women (Figure 1B). Serum leptin correlated with serum glucose (r = 
0.35, P < 0.01). 
Serum and CSF AgRP levels 
Serum AgRP levels were significantly lower in obese women than in normal weight women 
(Table 3). In contrast, CSF AgRP levels were significantly lower in normal weight women than in 
overweight or obese women (Table 3). Interestingly, simple linear regression analysis of the CSF-
AgRP concentration as a function of total energy intake showed a positive relationship between CSF-
AgRP and total energy intake (= 0.005, r = 0.39, P < 0.05) (Fig. 2D). The CSF/serum AgRP ratio 
was significantly higher in obese women than in normal weight women (Figure 1C). Accordingly, 
simple linear regression analysis of the CSF/serum AgRP ratio as a function of BMI showed a positive 
relationship between the ratio and BMI in the total population ( = 10.79, r = 0.43, P < 0.01) (Fig. 2E). 
The CSF/serum AgRP ratio correlated negatively with GWG (r = –0.37, P < 0.05) and positively with 
total energy intake (r = 0.36, P < 0.05).  
Serum POMC levels 
The serum levels of POMC did not differ between the groups (Table 3). However, POMC levels 
correlated with GWG (r = 0.37, P < 0.01) and birth weight (r = 0.26, P < 0.05). 
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Discussion 
This study shows that obese and overweight pregnant women have higher serum and CSF levels of 
leptin and higher CSF levels of AgRP and insulin than normal weight pregnant women. GWG was 
similar in all the three groups, but the infants of obese women had higher birth weight than infants of 
normal weight women. The obese women also had the highest insulin resistance with the lowest 
QUICKI values which also correlated with birth weights.  The CSF/serum leptin and the CSF/serum 
insulin ratios were lower, and the CSF/serum AgRP ratio was higher, in obese than in normal weight 
women. Additionally, CSF insulin, CSF/serum insulin ratio, CSF AgRP and serum and CSF leptin 
levels and the ratio correlated with QUICKI. Total energy intake was positively associated with CSF-
AgRP and CSF/serum AgRP ratio, and birth weight correlated with serum POMC in the women.  
Obese women, whose weight gain and total energy intake during the last 3 months of pregnancy 
were similar to those of normal and overweight women, seem to be protected from the suppressive 
effect of leptin and insulin by an increased CSF/serum AgRP ratio. This might be a way to secure the 
metabolic demands of pregnancy also in the obese women. 
BMI, GWG, total energy intake, and birth weight 
The three groups did not differ in self-reported energy intake or in the intake of carbohydrate, fat, 
and protein during the last 3 months of pregnancy, and, GWG was similar in all three groups. GWG 
tended to be lowest in obese women, but the difference was not significant, and their offspring had the 
highest birth weight. The average GWG in each of the three groups was in line with Swedish Medical 
Birth Registry for maternal body mass index class. These data also show that mean GWG decreases 
with increasing maternal BMI21. 
The infants of the obese women had higher birth weights. Birth weight correlated positively with 
plasma glucose values at term and negatively with QUICKI values. These correlations reflect the fetal 
nutrition supply, which increases with reduced insulin sensitivity and adiposity in the women. 
Maternal glucose levels, even if below those diagnostic of diabetes, are strongly and continuously 
associated with increased birth weight22. 
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Interestingly, we also found that serum POMC was positively associated with birth weight, which 
has to our knowledge, not been reported before. Normal gestation is associated with profound 
modifications of maternal corticotroph function. Plasma cortisol nearly doubles around mid-gestation 
and ACTH increases slightly. POMC is not found in nonpregnant women; it becomes measurable in 
early pregnancy, increases during the second trimester, and remains constant during the remaining 
gestation23. POMC plasma levels do not vary diurnally, are higher in multiple pregnancies and not 
affected by glucocorticoid administration, and return to normal levels within 3 days after birth, 
consistent with its placental origin23. However, the physiological function of POMC is unknown. 
POMC is primarily concentrated at the fetal–maternal interface24, pointing to a potential role in 
maternal and fetal nutrition and might in that way be connected to fetal growth. Further research is 
needed to understand its physiological role. 
Insulin sensitivity 
QUICKI values were significantly lower in obese women, reflecting their reduced insulin 
sensitivity, than in normal weight women. All women were normoglycemic and did not differ in 
fasting plasma glucose values; however, the obese women had greater insulin resistance and thus 
higher insulin levels. The obese women also had higher CSF insulin values and consistently lower 
CSF/serum insulin ratios. CSF insulin and plasma glucose were strongly associated in all groups. 
Insulin is transported from plasma to CSF by a saturable transport system that is very slow. Even 
after 4 h of superphysiologic levels of plasma insulin, CSF insulin levels are below fasting plasma 
insulin levels25. Because of its slow transport to the brain via the CSF circulation, insulin an 
improbable satiety signal. In addition to the correlation between obesity and CSF insulin levels, these 
findings suggest that insulin in the brain could, like leptin, be a continuing signal reporting on or 
regulating energy reserves, rather than an immediate satiety signal26. The transit of insulin from plasma 
to CSF is decreased in several animal models of insulin resistance27-29 but has not been studied in 
human pregnancy.  
Evidence of altered transport of insulin across the blood–brain barrier has been found in insulin-
resistant women with a high BMI15. As in our study, these results showed that blood and CSF 
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concentrations of insulin were correlated, and the ratio was positively associated with whole-body 
insulin sensitivity, which was also lower in insulin-resistant obese subjects. Insulin levels in this study 
were on average 92% lower in CSF than in serum15. In our study, mean insulin levels were 96% lower 
in CSF than serum; the CSF/serum insulin ratio ranged from 3.9% in the normal weight group to 2.9% 
in the obese pregnant women. Pregnancy is an insulin-resistant condition per se, which could explain 
the higher ratio in the women in our study than was reported in nonpregnant women15. A higher ratio 
during pregnancy, likely reflecting reduced transport, would counteract the feedback mechanisms of 
insulin in CNS that downregulate appetite and terminate food intake. This might be a mechanism to 
ensure that the metabolic needs of the developing fetus are met, in both insulin-resistant normal weight 
women and obese women. 
Leptin sensitivity 
We found that serum and CSF levels of leptin were strongly associated with BMI. The highest 
serum and CSF leptin levels and the lowest ratio were in the obese women. Interestingly, we found a 
similar pattern for CSF and serum insulin levels. Leptin resistance, like insulin resistance, with 
increased circulating leptin levels and concurrent hyperphagia, has been reported in both human and 
animal pregnancy studies30,31. In a recent study, leptin levels in serum and CSF were compared in 
pregnant and nonpregnant women of normal weight32. The serum levels were higher in the pregnant 
women, but the CSF leptin levels did not differ between the two groups, which consequently resulted 
in a lower CSF/serum leptin ratio in the pregnant women (~1% vs. 2.1% in nonpregnant women)32. 
We did not have a nonpregnant group, but the lowest ratio in the obese group was 1.3%. In another 
study33, lower ratios were found in healthy and preeclamptic pregnant women, and CSF and serum 
leptin levels correlated negatively. In contrast, in our study, CSF and serum leptin correlated 
positively, and the CSF levels were higher in overweight and the obese women than in normal weight 
women. 
We also found that CSF leptin and CSF/serum leptin correlated strongly with QUICKI values, 
although not as strongly as CSF insulin. The serum glucose values also correlated strongly with CSF 
insulin but not at all with CSF leptin. Both insulin and leptin act in the hypothalamus to enhance 
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peripheral insulin sensitivity and thereby decrease plasma glucose34. Similarly, in rats, leptin sensitizes 
the hypothalamus to insulin to regulate plasma glucose35. In that study, leptin infused directly into the 
CNS reduced hepatic glucose production in the liver and thereby lowered circulating glucose levels. 
Our findings might also mirror an indirect effect of leptin in the hypothalamus required to increase 
hypothalamic sensitivity to insulin to adjust plasma glucose. If this is an important interaction, leptin 
resistance during pregnancy might contribute to the insulin resistance that develops during pregnancy. 
Glucose is the most important fuel for fetal and placental tissues and is also important for maternal 
metabolism. Thus, the supply of glucose gets a metabolic priority for the pregnant woman, requiring 
adaptations to ensure that the glucose is continuously available in case of variations in maternal 
nutrition and insulin sensitivity. 
AgRP in serum and CSF 
The serum AgRP level was significantly lower in obese women than normal weight women, but 
the CSF AgRP level and the CSF/serum AgRP ratio were higher. In a recent study, AgRP was 
measured in CSF for the first time in human pregnancy and was found to be higher in normal weight 
women at term than in nonpregnant women32. Although both pregnant and nonpregnant subjects had 
comparable CSF leptin levels, absolute CSF AgRP levels were significantly higher in pregnant 
women, suggesting that leptin suppresses AgRP less effectively during pregnancy32. Increases in 
AgRP mRNA have also been consistently reported in the hypothalamus of rodents during 
pregnancy36,37. In rats, serum AgRP increase during pregnancy and do not decrease before delivery, 
implying that the placenta is the main source of AgRP in maternal serum18. These data also indicated 
that AgRP is a major factor for fetal development and for maternal energy expenditure during 
pregnancy. AgRP is usually present as a trimer and passes the blood–brain barrier very slowly38. Thus, 
peripheral AgRP probably does not directly regulate the secretion of different peptides in the brain but 
has long-lasting appetite-stimulating properties. Indeed, food intake increases after a single centrally 
administered dose of AgRP, and the effect lasts for up to a week; in contrast, the response to NPY lasts 
for hours rather than days39. 
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We found that CSF levels of AgRP and the CSF/serum AgRP ratio correlated strongly and 
positively with maternal BMI and were positively associated with total energy intake, pointing to the 
importance of AgRP in regulating energy status and food intake during pregnancy. Moreover, we 
found positive association with AgRP ratio and serum insulin and also with CSF/serum leptin ratio. 
These results are very interesting since cross-talk between the leptin and insulin signaling pathways in 
the hypothalamus appears to be important in the regulation of AgRP40,41. The forkhead transcription 
factor FOXO1, an important mediator of insulin signaling in peripheral tissues, is inactivated in the 
hypothalamus by both insulin and leptin40,41. Activation of hypothalamic FOXO1 blocks the action of 
both leptin and insulin and stimulates AgRP expression, resulting in increased food intake40,41. 
Compared with insulin and leptin, of which the high serum concentrations also resulted in higher CSF 
level, serum levels of AgRP were lower in obese subjects but resulted in higher CSF levels of AgRP. 
The only positive correlations that we found between energy intake and the other peptides measured 
were with CSF AgRP and the CSF/serum AgRP ratio. This finding suggesting the importance of this 
peptide in regulating energy expenditure and food intake during pregnancy and confirms findings in 
rodents18,42. Interestingly, serum AgRP levels correlated with GWG only in the obese group. Since 
GWG decreases with maternal BMI, and obese women tended to have the lowest GWG, AgRP might 
counteract the inhibitory effects of insulin and leptin and thereby ensure that the energy demands of 
obese pregnant women are met. 
The mechanisms of increased food intake during pregnancy are complicated and poorly 
understood, and few studies have been done in human pregnancies. Our study covers only a small 
portion of the complex interactions that drive the neuroendocrine adaptation to pregnancy; the brain is 
the site of action of many hormones originating from the ovary and placenta. Gonadal steroid 
hormones influence feeding behavior, and hyperphagia starts very early in pregnancy43, an important 
period that we have not studied. Nor have the short-term signals, including neural signals from the 
stomach and gut that help regulate meal size been studied. More research is therefore needed to 
confirm our results and to gain deeper insight in the neuroendocrine adaptations to pregnancy 
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Conclusion 
During pregnancy, metabolic interactions must be adapted to supply fetal nutritional demand and to 
store energy in preparation for the metabolic demands of lactation. These adaptations were important 
for human survival and prioritized in our evolutionary biologic history. In today’s “obesogenic” 
environment, with unlimited access to energy-rich foods, these adaptive processes may not be 
compatible with a healthy outcome of pregnancy. Obesity is now the most common clinical risk factor 
in obstetric practice. Our data suggest, for the first time in human pregnancy, that obese women, 
whose weight gain and total energy intake during the last 3 months of pregnancy were similar to those 
of normal and overweight women, are protected from the suppressive effect of leptin and insulin by an 
increased CSF/serum AgRP ratio. This might be a way to secure the metabolic demands of pregnancy 
in obese women. 
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Figure Legends 
Figure 1. CSF/serum ratios of insulin (A), leptin (B), and AgRP (C) concentrations in normal weight 
(NW, n = 26–30), overweight (OW, n = 19–20), and obese (OB, n = 14–22) pregnant women. Values 
are mean ± SEM. *p <0.05, **p <0.01 vs. normal weight women (independent sample t test). 
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Figure 2. Correlation between CSF AgRP and QUICKI (A) serum insulin and CSF leptin (B), CSF insulin 
and plasma glucose (C), total energy intake and CSF AgRP (D), and CSF/serum AgRP ratio and BMI (E) 
for the entire study population with no controlled variable. 
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TABLE 1. Maternal characteristics. 
 
 Group 
Characteristics Normal weight 
(n = 23–30) 
Overweight  
(n = 11–21) 
Obese group 
(n = 23) 
Age at Caesarean (years)  33 ± 0.8 34 ± 1.0 33 ± 0.9 
BMI at first antenatal visit (kg/m2) 22 ± 0.4 28 ± 0.3 33 ± 0.7 
Weight gain during pregnancy (kg) 15 ± 0.6 13 ± 1.1 12 ± 2.0 
Gestational age at birth (days) 254 ± 6 266 ± 5 254 ± 14 
Birth weight, offspring (g) 3551 ± 47 3609 ± 111 3779 ± 98* 
Total energy intake (kcal) 2637 ± 197 2691 ± 268 3265 ± 483 
Values are mean ± SEM.  
*P < 0.05 vs. normal weight women (independent sample t test). 
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TABLE 2. Insulin sensitivity 
 
 Group 
Characteristics Normal weight 
(n = 30) 
Overweight 
(n = 21) 
Obese 
(n = 17-23) 
Plasma glucose (mmol/l) 4.1 ± 0.1 4.0 ± 0.2 4.2 ± 0.1 
Serum insulin (mU/l)  8.1 ± 0.8 10.0 ± 1.4 14.4 ± 1.6** 
QUICKI 0.37 ± 0.0 0.36 ± 0.0 0.34 ± 0.0*** 
Values are mean ± SEM. 
 *P < 0.05, **P < 0.01 vs. normal weight women (independent sample t test). 
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TABLE 3. CSF concentrations of AgRP, insulin and leptin, and serum concentrations of AgRP, 




Values are mean ± SEM.  




Characteristics Normal weight 
(n = 26–39) 
Overweight 
(n = 18–21) 
Obese 
(n = 19–23) 
Serum    
   AgRP (pg/ml) 33.16 ± 2.2 33.08 ± 3.7 23.61 ± 2.6** 
   Leptin (ng/ml) 11.53 ± 0.9 16.48 ± 1.9* 19.54 ± 1.4*** 
   POMC (ng/ml) 1.81 ± 0.2 1.72 ± 0.4 1.56 ± 0.2 
CSF    
   AgRP (pg/ml) 20.29 ± 2.0 30.43 ± 3.3* 29.66 ± 3.4* 
   Insulin (mU/l) 0.29 ± 0.0 0.36 ± 0.0* 0.35 ± 0.0* 
   Leptin (ng/ml) 0.19 ± 0.0 0.25 ± 0.0* 0.26 ± 0.0** 
